Condition Directory

Leukemia clinical trials

Directory of U.S. ClinicalTrials.gov public records for Leukemia. Browse Leukemia recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 23, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

5289

Shown on this page

Current sort

How Leukemia studies are organized in the registry

“Leukemia” is an umbrella term; in practice most records name the specific subtype, and this directory has dedicated pages for the major ones — acute myeloid (AML), chronic lymphocytic (CLL), and acute lymphoblastic (ALL) leukemia. Use this page when scanning across subtypes, and the subtype pages when you know which disease you mean.

Terms that often appear in related listings

AML CLL ALL CML relapsed refractory

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 193–204 of 5,289 matching trials for Leukemia.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Interventions: Eltrombopag (EPAG); Drug
Lead sponsor: Abhay Singh, MD MPH; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
Interventions: None - Observational Study; Other
Lead sponsor: Tempus AI; Industry
Eligibility: 0 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 13
States / cities: Iowa City, Iowa • Bethesda, Maryland • St Louis, Missouri + 9 more

Conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Interventions: AUTO1; Biological
Lead sponsor: Autolus Limited; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 6 more

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
Interventions: revumenib, cobicistat; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 30 Days and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 22
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 17 more

Conditions: Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome, Refractory Secondary Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Fludarabine Phosphate, Melphalan, Multigated Acquisition Scan, Palifermin, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Sirolimus, Tacrolimus, Total Marrow and Lymphoid Irradiation; Procedure · Drug · Biological + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Duarte, California

Conditions: Myeloid Malignancy, Acute Myeloid Leukemia
Interventions: Venetoclax, Decitabine; Drug
Lead sponsor: Benjamin Tomlinson; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Hemophagocytic Lymphohistiocytoses, Primary Immunodeficiency Diseases, Hemoglobinopathies, Severe Aplastic Anemia, Cytopenia, Bone Marrow Failure Syndrome, Severe Chronic Active Epstein-Barr Virus Infection
Interventions: CliniMACS; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 55 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Houston, Texas

Conditions: B Acute Lymphoblastic Leukemia
Interventions: Autologous Anti-CD19 CAR-expressing T Lymphocytes, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Fludarabine, Leukapheresis, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 55 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Acute Myeloid Leukemia
Interventions: Bleximenib, Cytarabine, Daunorubicin or Idarubicin, Placebo; Drug
Lead sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland; Other
Eligibility: 18 Years and older
Enrollment: 875 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Orlando, Florida + 10 more

Conditions: T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Interventions: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Venetoclax, Vincristine Sulfate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Phase 2 Study, Blinatumomab, Acute Lymphoblastic Leukemia
Interventions: Blinatumomab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: AML (Acute Myeloid Leukemia)
Interventions: CHM-029; Drug
Lead sponsor: Charm Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Duarte, California • New Haven, Connecticut • Grand Rapids, Michigan

About this Leukemia clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Leukemia as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Leukemia.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Leukemia clinical trials

How Leukemia studies are organized in the registry

Filter and sort this condition

Live official records

Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia

A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

About this Leukemia clinical trials directory page